Pilot program to provide cheaper GLP-1 via Medicare stokes shortage fears

A new pilot program, Medicare GLP-1 Bridge, launching July 1st, will allow some Medicare beneficiaries aged 65 and above to access GLP-1 drugs for $50 per month. This temporary program aims to help older adults struggling with obesity and other conditions afford these popular and effective medications, which can cost significantly more. The program will cover specific GLP-1 drugs for individuals meeting certain BMI requirements and without specific pre-existing conditions already covered by their drug plans. While welcomed by doctors and patients like Kathryn, who found relief from obesity but faced high costs, concerns remain about the program's administration, potential drug shortages due to increased demand, and what will happen when the program ends in 2027, as obesity is a chronic condition.

Medicare is now covering certain GLP-1 weight loss drugs for $50 per month through a temporary trial program called Medicare GLP-1 Bridge, running until the end of 2027. This program offers access to medications like Wegovy and Zepbound for eligible Medicare and Medicare Advantage beneficiaries who meet specific body mass index (BMI) and health condition requirements, and who are not already covered for these drugs for other conditions like diabetes. The Centers for Medicare & Medicaid Services (CMS) hopes this initiative will collect data to inform potential longer-term coverage options. To qualify, beneficiaries must have a BMI of 35 or higher, or a BMI of 27 or higher with an additional health condition, and cannot have existing coverage for GLP-1s due to conditions like sleep apnea or diabetes. The program aims to reduce the cost barrier for older Americans seeking weight loss treatment, though its long-term future depends on data collected during the trial and potential Congressional action.